A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

We hoped industry layoffs would relent in ... Story Feb. 6 - X4 Pharmaceuticals: The rare disease biotech is laying off 43 employees—equivalent to 30% of the company’s total staffers—along ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

By fusing circular dichroism with high-resolution microspectroscopy and microscopic imaging, this cutting-edge technology is ...

Dr. Arum Han, the Texas Instruments Professor in the Department of Electrical and Computer Engineering, and his lab, created a technology named NOVAsort (Next-generation Opto-Volume-based Accurate ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, ...

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners ... In comparison, Massachusetts-based biotech companies ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Several members of our firm’s life sciences team were on the ground at the 43rd Annual J.P. Morgan Healthcare Conference in ...